title: Laminin modified infection-preventing collagen membrane containing silver sulfadiazine-hyaluronan microparticles.
abstract: The newly developed laminin modified infection-preventing collagen membrane consists of a 3 component laminate, comprising 2 outer collagen layers and a central laminin layer. The 2 outer collagen layers (dense and porous layers) were fabricated by air-drying and freeze drying, respectively, and the laminin layer was formed by a straightforward liquid coating method. In addition, hyaluronan based microparticles containing silver sulfadiazine (AgSD) were incorporated into the 2 collagen layers (AgSD content 50 microg/cm2). Laminin coated collagen surfaces did not promote fibroblast attachment but showed a retarded fibroblast proliferation rate and an increased rate of collagen synthesis versus pure collagen surfaces. In an animal study, a laminin coating on a nonmedicated collagen membrane significantly increased both wound size reduction and vessel proliferation 7 days after application versus polyurethane film. Interestingly, the laminin coated AgSD medicated collagen membrane demonstrated higher wound size reduction and vessel proliferation and lower inflammation than the polyurethane control, suggesting that the laminin AgSD medicated collagen membrane substantially improves dermal wound healing.
authors.affiliation: Department of Medical Engineering, Yonsei University College of Medicine, Seoul, Korea.
authors.forename: Jong-Eun
authors.initials: JE
authors.lastname: Lee
authors.forename: Jong-Chul
authors.initials: JC
authors.lastname: Park
authors.forename: Kwang Hoon
authors.initials: KH
authors.lastname: Lee
authors.forename: Sang Ho
authors.initials: SH
authors.lastname: Oh
authors.forename: Hwal
authors.initials: H
authors.lastname: Suh
mesh_terms: D000276:Adjuvants, Immunologic / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D000891:Anti-Infective Agents, Local / Q000494:pharmacology* / Q000627:therapeutic use; D001458:Bandages; D003094:Collagen / Q000494:pharmacology* / Q000627:therapeutic use; D004195:Disease Models, Animal; D005347:Fibroblasts / Q000187:drug effects*; D006168:Guinea Pigs; D006801:Humans; D006820:Hyaluronic Acid / Q000494:pharmacology* / Q000627:therapeutic use; D066298:In Vitro Techniques; D017053:Infection Control; D007797:Laminin / Q000494:pharmacology* / Q000627:therapeutic use; D008863:Microspheres; D012837:Silver Sulfadiazine / Q000494:pharmacology* / Q000627:therapeutic use; D014945:Wound Healing / Q000187:drug effects*
chemical_list: D000276:Adjuvants, Immunologic; D000891:Anti-Infective Agents, Local; D007797:Laminin; D006820:Hyaluronic Acid; D003094:Collagen; D012837:Silver Sulfadiazine